Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab

Published:2025-03 Issue: Volume:7 Page:100106
ISSN:2949-8201
Container-title:ESMO Real World Data and Digital Oncology
language:en
Short-container-title:ESMO Real World Data and Digital Oncology

Author:

Oshima M.,Washino S.,Shirotake S.,Takeshita H.,Inoue M.,Miura Y.,Nakayama A.,Nagamoto S.,Nakayama T.,Izumi K.,Oyama M.,Kawakami S.,Saito K.,Matsuoka Y.,Miyagawa T.

Publisher

Elsevier BV

Reference36 articles.

1. European association of urology guidelines on renal cell carcinoma: the 2022 update;Ljungberg;Eur Urol,2022

2. Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology;Motzer;J Natl Compr Canc Netw,2022

3. Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data;Yanagisawa;Cancer Immunol Immunother,2024

4. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial;Albiges;ESMO Open,2020

5. Navigating the ICI combination treatment journey: patterns of response and progression to first-line ICI-based combination treatment in metastatic renal cell carcinoma;Samuelly;J Clin Med,2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.7亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP